Inozyme reports Q3 EPS (39c), consensus (44c)

“As we close in on the end of a highly productive year, our focus remains firmly on advancing INZ-701 across each of our clinical programs,” said Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme (INZY) Pharma. “The recent presentation of promising interim data from our Phase 1 data from our calciphylaxis program highlights our progress, and we remain on track to report interim data from our Phase 1b ENERGY 1 trial in ENPP1 Deficiency by year-end. With a growing body of clinical evidence supporting the potential for INZ-701 to serve as a meaningful therapy across multiple indications of high unmet need, we are committed to our mission to bring novel treatment options to patients facing rare diseases affecting bone health and blood vessel function.”